Streetbeat News

Products Services

ARGX

Argenx shares are trading higher following the FDA approval of VYVGART Hytrulo for treating chronic inflammatory demyelinating polyneuropathy.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 1:03 pm

RXRX

Helix and Recursion Pharmaceuticals have entered a multi-year agreement to leverage Helix's clinico-genomic data for AI-driven drug discovery. This partnership aims to enhance the creation and training of AI models in the field of precision medicine.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 1:03 pm

REVB

Revelation Biosciences announced positive Phase 1 results for its Gemini program, demonstrating safety, tolerability, and dose-dependent biomarker changes. These results enable further development across multiple indications.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 1:02 pm

HUBC

HUB Cyber Security Ltd. (NASDAQ:HUBC) announced securing two deals with governmental entities, emphasizing its strategic expansion and enhancement of offerings. The company expects significant progress in its secure data fabric vertical by the end of the next quarter and plans to release its annual financial reports soon.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:59 pm

FXI

NVO

China's Medical Products Authority has approved Novo Nordisk's Type-2 diabetes treatment for entry into the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:57 pm

AIQ

AVEM

BABA

Alibaba Cloud has introduced an AI programmer powered by its self-developed large language model to speed up app development. This innovation aims to reduce development time significantly, though it has received mixed reactions from human programmers. Alibaba's stock has faced challenges, losing 14% in the last year, but analysts predict a potential upside. Investors can gain exposure to Alibaba through ETFs like AVEM and AIQ.

Portfolio Pulse from Anusuya Lahiri

June 24, 2024 | 12:54 pm

FXI

NVO

China's Medical Products Authority has approved Novo Nordisk's Type-2 diabetes treatment for entry into the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:53 pm

ANIX

Anixa Biosciences has treated the sixth patient in its ongoing Phase 1 clinical trial of Chimeric Antigen Receptor T-Cell (CAR-T) therapy for ovarian cancer. This marks a significant milestone in the development of their innovative cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:46 pm

AAPL

ANET

COHR

DELL

SMCI

JPMorgan analyst Samik Chatterjee highlights Apple, Arista Networks, Coherent Corp, Dell Technologies, and Super Micro Computer as top picks in the AI hardware sector. Apple is noted for its underappreciated potential in AI-led hardware upgrades, while Arista, Coherent, Dell, and Super Micro are recognized for their strong positions in high-margin AI segments.

Portfolio Pulse from Surbhi Jain

June 24, 2024 | 12:42 pm

ZPTA

Zapata AI has joined the KT Consortium to collaborate with leading chemical and biochemical manufacturers such as Henkel, Mitsubishi Chemical, and Syngenta. The collaboration aims to accelerate chemical compound development and manufacturing using advanced technologies like optimization, virtual sensors, predictive modeling, and generative AI.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:40 pm